Clinical research
AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.
The letter was related to a 2021 FDA inspection connected to Sesen’s Biologics License Application for Vicineum. Read more about this sesen bio news here.
The 643-participant study failed to reach statistical significance in its co-primary cognitive and functional endpoints, ADAS-Cog11 and ADCS-ADL, at end of treatment.
The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.
A large number of people were waiting for the breast cancer vaccine. Now, at present, the world has witnessed the first potential vaccine. Let’s take a look at it.
Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.
Pennsylvania-based Ocugen has submitted an Investigational New Drug (IND) to the FDA to run a Phase III trial of India’s BBV152 (Covaxin), a vaccine against COVID-19.
The clinical study on ANG-3777 demonstrated a modest but not clinically significant difference in the placebo group’s estimated glomerular filtration rate.
On Tuesday morning, Provention Bio announced positive interim results from its Phase I PROVENT study of PRV-101.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
PRESS RELEASES